DSGN

DESIGN THERAPEUTICS INC

DSGN·25056L103·US·Common Stock·Healthcare - Biotechnology-Activist

DSGN (DESIGN THERAPEUTICS INC) is held by 81 institutional investors as of Q2 2026. Largest holders: BAKER BROS. ADVISORS LP ($38.8M), DRIEHAUS CAPITAL MANAGEMENT LLC ($38.5M), BlackRock, Inc. ($38.5M). Net institutional sentiment: Mixed.

81
Holders
(6 Elite)
$334.6M
Total Value
65% (83)
Consensus
54 buying - 29 selling
13F: Insider & Congress: Updated regularly
DSGN

Smart Money Verdict

View all
Loading verdict
Held by 81 funds
6 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Aug 14, 2025 · Activists Aug 14, 2026 · Congress none

ActivistSISirenia Capital Management LP9.5%Aug 14, 2026
ActivistPoint72 Asset Management, L.P.Point72 Asset Management, L.P.3.8%Aug 14, 2026
ActivistPoint72 Asset Management, L.P.Point72 Asset Management, L.P.5.1%Jun 9, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
2.7M(+3.6%)$38.8M0.2%+50.31%
36
Increased
2.7M(+52.5%)$38.5M0.2%+60.37%
49
Increased
2.7M(+24.7%)$38.5M0.0%+96.47%
36
Decreased
2.4M(-13.1%)$34.2M0.0%+116.31%
0
Increased
1.6M(+16.4%)$22.7M0.0%+46.67%
33
Increased
1.1M(+1189.5%)$16.2M0.1%+10.38%
45
Increased
958,417(+38.4%)$13.9M0.0%+1.80%
37
Decreased
776,462(-2.8%)$11.2M0.0%+142.45%
0
Increased
765,425(+16.6%)$11.1M0.0%+71.12%
32
Increased
736,221(+11.6%)$10.7M0.0%+264.67%
31
Decreased
700,354(-27.2%)$10.1M0.0%+152.72%
0
Increased
694,743(+60.9%)$10.1M0.0%+61.79%
40
Increased
656,584(+30.1%)$9.5M0.0%+63.61%
35
Increased
565,597(+95.5%)$8.2M0.0%+28.73%
44
Increased
437,079(+1178.6%)$6.3M0.0%+10.41%
44
Decreased
387,913(-5.0%)$5.6M0.0%+187.11%
0
Increased
353,197(+17.6%)$5.1M0.0%+9.06%
31
Increased
271,264(+12.3%)$3.9M0.0%+10.38%
30
Increased
251,442(+81.5%)$3.6M0.0%+29.84%
41
Increased
230,202(+17.7%)$3.3M0.0%+46.10%
31

Showing 1-20 of 88

1 / 5
DSGNDSGNDESIGN THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used